FRANCESCHINI, Franco
 Distribuzione geografica
Continente #
NA - Nord America 11.171
EU - Europa 8.746
AS - Asia 4.008
SA - Sud America 29
AF - Africa 26
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 14
AN - Antartide 1
Totale 24.014
Nazione #
US - Stati Uniti d'America 11.122
IT - Italia 4.069
CN - Cina 1.643
UA - Ucraina 1.441
HK - Hong Kong 953
SG - Singapore 917
DE - Germania 896
FI - Finlandia 479
RU - Federazione Russa 391
IE - Irlanda 362
GB - Regno Unito 338
TR - Turchia 326
FR - Francia 273
PL - Polonia 137
SE - Svezia 101
IN - India 68
BE - Belgio 45
CA - Canada 44
NL - Olanda 37
ES - Italia 26
EE - Estonia 23
RO - Romania 18
AU - Australia 16
BR - Brasile 16
CZ - Repubblica Ceca 16
CH - Svizzera 14
EU - Europa 14
VN - Vietnam 14
ID - Indonesia 13
HR - Croazia 11
MK - Macedonia 11
EG - Egitto 10
GR - Grecia 10
IR - Iran 9
JP - Giappone 9
SA - Arabia Saudita 9
LU - Lussemburgo 8
PK - Pakistan 8
IL - Israele 7
LT - Lituania 7
SK - Slovacchia (Repubblica Slovacca) 6
AT - Austria 5
CI - Costa d'Avorio 5
PH - Filippine 5
UG - Uganda 5
AM - Armenia 4
BG - Bulgaria 4
CL - Cile 4
RS - Serbia 4
AR - Argentina 3
JO - Giordania 3
LI - Liechtenstein 3
MU - Mauritius 3
MX - Messico 3
NZ - Nuova Zelanda 3
PE - Perù 3
SI - Slovenia 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
CY - Cipro 2
DK - Danimarca 2
IQ - Iraq 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MA - Marocco 2
PT - Portogallo 2
UZ - Uzbekistan 2
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
CO - Colombia 1
CR - Costa Rica 1
DZ - Algeria 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HU - Ungheria 1
KH - Cambogia 1
MS - Montserrat 1
MY - Malesia 1
NO - Norvegia 1
VE - Venezuela 1
Totale 24.014
Città #
Fairfield 1.572
Woodbridge 1.143
Jacksonville 1.085
Hong Kong 951
Ashburn 807
Houston 794
Singapore 739
Cambridge 625
Seattle 589
Ann Arbor 587
Wilmington 563
Princeton 549
Chandler 477
Nanjing 350
Helsinki 322
Milan 301
Dublin 294
Istanbul 292
Beijing 287
New York 278
Brescia 182
Rome 181
Moscow 149
Warsaw 130
Nanchang 121
San Diego 110
Des Moines 105
Hebei 105
Florence 100
Shenyang 99
Shanghai 84
Changsha 80
Tianjin 74
Jinan 67
Jiaxing 63
Verona 61
London 56
Trieste 54
Munich 53
Turin 52
Hangzhou 48
Bergamo 44
Los Angeles 44
Dearborn 42
San Francisco 42
Brussels 41
Lancaster 38
Genoa 35
Udine 34
Romola 33
Kunming 32
Ningbo 32
Padova 30
Bologna 28
Toronto 27
Lappeenranta 26
Falkenstein 24
Genova 24
Pisa 24
Taizhou 23
Tallinn 23
Zhengzhou 23
Haikou 22
Lanzhou 22
Kocaeli 21
Syracuse 21
Boardman 20
Menlo Park 20
Guangzhou 19
Torino 19
Nürnberg 18
Reggio Nell'emilia 18
Mumbai 17
Naples 17
Redwood City 17
Rozzano 17
Modena 16
Palermo 16
Trento 16
Norwalk 15
Orange 15
Washington 15
Bari 14
Brno 14
Dong Ket 14
Monmouth Junction 14
Paris 14
Pune 14
Desio 13
San Mateo 13
Venice 13
Jakarta 12
Kilburn 12
Catania 11
Dallas 11
Ferrara 11
Pordenone 11
Rho 11
Split 11
Cosenza 10
Totale 15.832
Nome #
ANTICORPI ANTI-TH/TO NELLA SCLEROSI SISTEMICA (SSC): CORRELAZIONI CLINICHE E IMMUNOLOGICHE 2.169
ANTICORPI ANTI-RNA POLIMERASI III: UN MARKER DI ESORDIO PRECOCE DI SCLEROSI SISTEMICA 1.592
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 242
Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI 161
Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens. 159
Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease? 155
Anti-RNA polymerase III antibodies as a risk marker for early Gastric Antral Vascular Ectasia (GAVE) in systemic sclerosis 147
Prevalence and disease-specific risk factors for Lower Urinary Tract symptoms in Systemic Sclerosis: an international multi-centric study 139
Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression 136
Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study 134
Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality 133
Antiphospholipid antibodies mediate autoimmunity against dying cells. 129
Systemic lupus erythematosus and endothelial dysfunction: A close relationship 128
Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies 128
Endothelial dysfunction in early systemic lupus erythematosus patients and controls without previous cardiovascular events 126
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 125
Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). 123
Macrophage activation syndrome in adult systemic lupus erythematosus: Report of seven adult cases from a single Italian rheumatology center 123
C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis 122
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group 121
Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. 120
The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study 120
The clinico-serological spectrum of overlap myositis 120
Treatment and functional outcome of patients with cystoid macular edema: a single-center experience 118
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 118
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years 117
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab 117
Endothelial Dysfunction In Early Systemic Lupus Erythematosus Patients And Controls Without Previous Cardiovascular Events. 116
Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. 116
Autoimmune polyendocrine Syndromes 114
Discordance for systemic lupus erythematosus and hyper IgE syndrome in a pair of monozygotic twins 112
Relationship between endothelial dysfunction, videocapillaroscopy and circulating CD3+CD31+CXCR4+ lymphocytes in systemic lupus erythematosus without cardiovascular risk factors 112
Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. 110
Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera 110
Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: The positive experience of a national multicentre study 109
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 109
Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. 109
Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus. 108
Aortic stiffness and left ventricular hypertrophy in rheumatoid arthritis: Comment on the article by Rudominer et al. 107
Rare autoantibodies to cellular antigens in systemic lupus erythematosus. 107
Endothelial Dysfunction In Early Systemic Lupus Erythematosus Patients And Controls Without Previous Cardiovascular Events 107
Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis 107
Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures 106
Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences? 106
Severe skin involvement in type II cryoglobulinemia successfully treated with thalidomide 103
Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women 103
Antiphospholipid syndrome and glomerular thrombosis in the absence of overt lupus nephritis 102
The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. 102
The 2016 classification criteria for primary Sjogren's syndrome: What's new? 102
Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. 101
METODICHE AUTOMATIZZATE PER ANTICORPI ANTINUCLEO (ANA): E' POSSIBILE SOSTITUIRE L'IMMUNOFLUORESCENZA INDIRETTA? 101
[Neonatal lupus: clinical features and risk of congenital cardiac heart block in newborns from mothers with anti Ro/SSA antibodies] 101
Chilblain lupus erythematosus is associated with antibodies to SSA/Ro. 100
Celiac Disease Prevalence is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study 100
Myositis autoantibodies and clinical phenotypes 99
Incidence of antiperinuclear factor in patients with psoriatic arthritis. 98
The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus 98
Antiperinuclear factor in psoriatic arthropathy 95
Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference 95
Pathogenetic associations of maternal anti-Ro/SSA antibodies. 94
In vivo reflectance confocal microscopy features of cutaneous microcirculation and epidermal and dermal changes in diffuse systemic sclerosis and correlation with histological and videocapillaroscopic findings. 94
Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. 93
Primary biliary cirrhosis-related autoantibodies in a large cohort of italian patients with systemic sclerosis 93
Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study 93
Anti-Ro/SSA and La/SSB antibodies 93
Elastic properties of the ascending aorta in patients with rheumatoid arthritis. 92
Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. 92
International cohort study of 73 anti-Ku-positive patients: Association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis 92
Serum prealbumin is an independent predictor of mortality in systemic sclerosis outpatients 92
Anti-topoisomerase-I antibodies in systemic lupus erythematosus and potential association with the presence of anti-dsDNA antibodies 92
Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. 91
Autoantibodies to survival of motor neuron complex in patients with polymyositis: Immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins 91
Cardiological features in idiopathic inflammatory myopathies. 90
The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus 90
Determination of antibodies to extractable nuclear antigens by commercial kits: a multicenter study 90
Update on Antiphospholipid Syndrome: Ten Topics in 2017 90
Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety 89
Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. 88
Antinuclear antibodies in Frontotemporal Dementia: the tip's of autoimmunity iceberg? 88
Serologic profile and mortality rates of scleroderma renal crisis in Italy 87
Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies. 87
Incidence of antiperinuclear factor in sera of patients with psoriatic arthritis 86
DECREASED TITER OF ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR AND REDUCTION OF POSTSWITCH MEMORY B CELLS AFTER ABATACEPT TREATMENT FOR RHEUMATOID ARTHRITIS 86
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 86
Echocardiographic Evaluation of Asymptomatic Patients Affected by Rheumatoid Arthritis 85
Rheumatoid arthritis and diabetes mellitus: Two faces of one coin? Comment on the article by Peters et al 85
Belimumab decreases flare rate and hinders the expected damage progression in patients with active systemic lupus erythematosus 84
Retention of a bile acid analogue in the enterohepatic circulation (EHC) in primary biliary cirrhosis (PBC): comparison with normal controls and effect of bile acid treatment. 83
Evaluation of Ascending Aorta Wall in Rheumatoid Arthritis by Tissue and Strain Doppler Imaging During Anti-Tumor Necrosis Factor-α Therapy 83
Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. 82
Clinical and morphological features of kidney involvement in primary Sjogren's syndrome. 82
Neutrophil Extracellular Traps (NETs) profiles in patients with incident SLE and lupus nephritis 82
Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. 82
Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. 82
Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis 81
Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. 81
Elastic properties of the ascending aorta in patients with rheumatoid arthritis. 81
Transient neonatal bradycardia without heart block associated with anti-Ro antibodies 81
LUPUS ERITEMATOSO SISTEMICO AD ESORDIO TARDIVO: CARATTERISTICHE CLINICHE ED IMMUNOLOGICHE 81
Deforming arthropathy of the hands in Systemic Lupus Erythematosus is associated with antibodies to SS-A/Ro and to SS-B/La. 80
Totale 14.061
Categoria #
all - tutte 134.509
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 134.509


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.572 0 0 0 0 0 0 414 538 384 748 166 322
2020/20214.009 94 438 162 444 242 467 156 446 466 472 395 227
2021/20223.010 185 401 140 176 164 200 201 234 193 296 272 548
2022/20232.266 341 38 51 99 194 564 47 229 384 56 139 124
2023/20242.853 150 84 228 246 134 458 134 138 667 94 107 413
2024/20252.846 117 156 125 734 678 589 447 0 0 0 0 0
Totale 24.506